Cargando…
In-silico analysis of potent Mosquirix vaccine adjuvant leads
BACKGROUND: World Health Organization recommend the use of malaria vaccine, Mosquirix, as a malaria prevention strategy. However, Mosquirix has failed to reduce the global burden of malaria because of its inefficacy. The Mosquirix vaccine’s modest effectiveness against malaria, 36% among kids aged 5...
Autores principales: | Onyango, Okello Harrison, Mwenda, Cynthia Mugo, Gitau, Grace, Muoma, John, Okoth, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689608/ https://www.ncbi.nlm.nih.gov/pubmed/38032502 http://dx.doi.org/10.1186/s43141-023-00590-x |
Ejemplares similares
-
Mosquirix™ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy
por: Nadeem, Aroosa Younis, et al.
Publicado: (2022) -
Musings on malaria morbidity and mortality after the new Mosquirix(®) vaccine
por: Sackey, Adziri H
Publicado: (2019) -
Re: Musings on malaria morbidity and mortality after the new Mosquirix(®) vaccine
por: Asante, Kwaku Poku, et al.
Publicado: (2019) -
RTS,S/AS01 malaria vaccine (Mosquirix(®)): a profile of its use
por: Syed, Yahiya Y.
Publicado: (2022) -
In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review
por: Onyango, Okello Harrison
Publicado: (2023)